← Back to Clinical Trials
Recruiting NCT07288684

NCT07288684 Chiropractor Delivered Virtual Intervention After Vertebral frActure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07288684
Status Recruiting
Phase
Sponsor University of Waterloo
Condition Osteoporosis
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2025-10-20
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
VIVA

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2025-10-20 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Eligibility Criteria

Inclusion Criteria: * Over the age of 50 (men or post-menopausal women) * Have had a vertebral fracture in the past two years * Willing to participate in twelve (12) virtual rehabilitation sessions for 10 weeks * Have access to internet and a smart device with a camera and microphone Exclusion Criteria: * Cauda equina syndrome or spinal cord injury * Had a traumatic fracture (i.e., car accident) * An active infection * Active inflammatory arthritis with a flare up within the past two years * An inability to follow two-step commands or understand instructions and are without a caregiver to support participation * Been participating in a similar rehabilitation program for vertebral fractures delivered by a physical therapist, exercise physiologist or kinesiologist and includes exercise * Any surgeries planned or health problems that might cause their health to change significantly in the next 3 months

Contact & Investigator

Central Contact

Allison A Legg

✉ a2legg@uwaterloo.ca

📞 289-380-0859

Frequently Asked Questions

Who can join the NCT07288684 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07288684 currently recruiting?

Yes, NCT07288684 is actively recruiting participants. Contact the research team at a2legg@uwaterloo.ca for enrollment information.

Where is the NCT07288684 trial being conducted?

This trial is being conducted at Waterloo, Canada.

Who is sponsoring the NCT07288684 clinical trial?

NCT07288684 is sponsored by University of Waterloo. The trial plans to enroll 15 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology